scholarly journals Pharmacokinetics and Drug‐Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping

2020 ◽  
Author(s):  
Kamunkhwala Gausi ◽  
Lubbe Wiesner ◽  
Jennifer Norman ◽  
Carole L. Wallis ◽  
Carolyne Onyango‐Makumbi ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Pregnant Women ◽  
Women Living With Hiv ◽  
Living With Hiv

scholarly journals Drug–Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?

2020 ◽  
Vol 59 (10) ◽  
pp. 1217-1236
Author(s):  
Vera E. Bukkems ◽  
Angela Colbers ◽  
Catia Marzolini ◽  
Jose Molto ◽  
David M. Burger
Keyword(s):  
Drug Interactions ◽  
Pregnant Women ◽  
Antiretroviral Drugs ◽  
Women Living With Hiv ◽  
Living With Hiv

Social Vulnerability among Foreign-Born Pregnant Women and Maternal Virologic Control of HIV

2020 ◽  
Author(s):  
Ashish Premkumar ◽  
Lynn M. Yee ◽  
Lia Benes ◽  
Emily S. Miller
Keyword(s):  
Antiretroviral Therapy ◽  
Pregnant Women ◽  
Median Time ◽  
Social Vulnerability ◽  
Viral Suppression ◽  
Foreign Born ◽  
Women Living With Hiv ◽  
Virologic Control ◽  
Clinical Records ◽  
Living With Hiv

Objective The aim of this study was to assess whether social vulnerability among foreign-born pregnant women living with HIV is associated with maternal viremia during pregnancy. Study Design This retrospective cohort study included all foreign-born pregnant women living with HIV who received prenatal care in a multidisciplinary prenatal clinic between 2009 and 2018. A licensed clinical social worker evaluated all women and kept detailed clinical records on immigration status and social support. Social vulnerability was defined as both living in the United States for less than 5 years and reporting no family or friends for support. The primary outcome was evidence of viral non-suppression after achievement of initial suppression. Secondary outcomes were the proportion of women who required > 12 weeks after starting antiretroviral therapy to achieve viral suppression, median time to first viral suppression (in weeks) after initiation of antiretroviral therapy, and the proportion who missed ≥ 5 doses of antiretroviral therapy. Bivariable analyses were performed. Results A total of 111 foreign-born women were eligible for analysis, of whom 25 (23%) were classified as socially vulnerable. Social and clinical characteristics of women diverged by social vulnerability categorization but no differences reached statistical significance. On bivariable analysis, socially-vulnerable women were at increased risk for needing > 12 weeks to achieve viral suppression (relative risk: 1.78, 95% confidence interval: 1.18–2.67), though there was no association with missing ≥ 5 doses of antiretroviral therapy or median time to viral suppression after initiation of antiretroviral therapy. Conclusion Among foreign-born, pregnant women living with HIV, markers of virologic control during pregnancy were noted to be worse among socially-vulnerable women. Insofar as maternal viremia is the predominant driver of perinatal transmission, closer clinical surveillance and support may be indicated in this population. Key Points

scholarly journals Prevalence of Drug–Drug Interactions with Hormonal Contraceptives and Antiretrovirals in Women Living with HIV

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S662-S662
Author(s):  
Milena M McLaughlin ◽  
Ashley Jensen ◽  
Susan Cohn ◽  
Kristin Darin
Keyword(s):  
Drug Interactions ◽  
Hormonal Contraceptives ◽  
Women Living With Hiv ◽  
Living With Hiv

scholarly journals Quality of Life of Pregnant Women Living with HIV/AIDS

2016 ◽  
Vol 38 (05) ◽  
pp. 246-252 ◽  
Author(s):  
Mariângela Silveira ◽  
Cristina Müller ◽  
Marysabel Silveira
Keyword(s):  
Quality Of Life ◽  
Pregnant Women ◽  
Women Living With Hiv ◽  
Living With Hiv ◽  
Hiv Aids

Group Antenatal Care for Improving Retention of Adolescent and Young Pregnant Women Living With HIV in Kenya

2021 ◽  
Author(s):  
Chloe A. Teasdale ◽  
Judith Odondi ◽  
Catherine Kidiga ◽  
Michelle Choy ◽  
Ruby Fayorsey ◽  
...  
Keyword(s):  
Antenatal Care ◽  
Pregnant Women ◽  
Women Living With Hiv ◽  
Living With Hiv

Antiretroviral Therapy in Pregnant Women

2019 ◽  
pp. 281-286
Author(s):  
William R. Short ◽  
Jason J. Schafer
Keyword(s):  
Clinical Trials ◽  
Pregnant Women ◽  
Hiv Transmission ◽  
Pediatric Aids ◽  
Women Living With Hiv ◽  
Pivotal Study ◽  
Aids Clinical Trials ◽  
Living With Hiv ◽  
Mother To Child ◽  
Over Time

Upon completion of this chapter, the reader should be able to describe the appropriate management of antiretrovirals for pregnant women living with HIV. Over time, research has demonstrated that proper prevention strategies and interventions during pregnancy, labor, and delivery can significantly reduce the rate of mother-to-child transmission (MTCT) of HIV. In 1994, a pivotal study in the field of HIV medicine, the Pediatric AIDS Clinical Trials Group 076, demonstrated that the use of zidovudine (ZDV) monotherapy during pregnancy substantially reduced the risk of HIV transmission to infants by 67% (...

Sign in / Sign up

Export Citation Format

Share Document